We are currently recruiting for a study on Alzheimer's Disease
Alzheimer’s disease is a brain disorder that slowly destroys an individual's memory and thinking skills, and eventually their ability to carry out simple tasks. Symptoms gradually worsen over a number of years and in its early stages memory loss is mild. With late-stage Alzheimer’s individuals can lose the ability to respond to their environment.
Current therapies may provide symptomatic relief from cognitive difficulties however, they provide only modest efficacy and are accompanied by dose-limiting tolerability issues, such as nausea, vomiting, diarrhoea, muscle cramps and general malaise.
The only therapy currently available in New Zealand is Donepezil, which is designed to enhance cognitive function.
This study will investigate if the early intervention of the investigative product can help to prevent the condition from deteriorating.
If you, or somebody you know, are interested in taking part in a clinical trial, register here to receive updates and our CGM Research Trust newsletter, call us on 03 365 6777, or contact us.
Are you currently aged between 55-90?
Have Been diagnosed with mild to moderate Alzheimer's disease?
are currently taking donepezil?
If you have answered YES to the questions above, you may be eligible to be part of a new trial being held in Christchurch. This trial will investigate if the early intervention of the investigative product can help to prevent the condition from deteriorating.
If you're interested in learning more about the study, please fill out the form below or call us on 03 365 6777
We are presently involved in looking at the area of memory and what can be done to help counter short term memory loss. We're working alongside pharmaceutical companies in trialling new treatments.